Adrenocortical carcinoma is a rare cause of Cushing's syndrome. Its aggressive behavior leads to a poor prognosis. Mitotane (o,p′-DDD) is the mainstay of medical therapy, but the adverse effects often limit its use. We report on a patient with adrenocortical carcinoma who was treated with mitotane. A 42-year-old woman presented with Cushing's syndrome and hirsutism. There were lung metastases at diagnosis. Right radical adrenalectomy and multiple lung metastatectomy were performed. Six months later, mitotane was administered for widely-disseminated metastases. It was discontinued because of severe side effects including dizziness, headache, generalized weakness, nausea, and vomiting. The patient died of hepatic failure one year after diagnosis. In these patients, mitotane may be used immediately after surgical resection as an adjuvant therapy if residual tumors were considered. A low-dose mitotane regimen should be given with monitoring of the serum level of the drug to obtain an optimal effect. Systemic chemotherapy may be administered or combined with mitotane if the tumor is poorly responsive to mitotane or the patient can not tolerate the drug. More experience is needed to determine the effect of various treatments.
|Number of pages||5|
|Journal||Tzu Chi Medical Journal|
|Publication status||Published - Apr 2005|
- Adrenocortical carcinoma
- Cushing's syndrome
- Lung metastasis
ASJC Scopus subject areas